Professor Johan Vansteenkiste, an associate Editor of Annals of Oncology, discusses the recent publication of Felip et al. that reports a study of the intracranial, and extracranial efficacy of lorlatinib, a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI)in ALK-positive NSCLC that progressed on second-generation ALK TKIs.
Felip E et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol 2021; 32: https://doi.org/10.1016/j.annonc.2021.02.012
Stinchcombe TE. Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.  Ann Oncol 2021; 32: https://doi.org/10.1016/j.annonc.2021.03.002

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive NSCLC

In this Article of the Month podcast Annals of Oncology Editor-in-Chief discusses the ENGOT-en11/GOG-3053/KEYNOTE-B21 trial with Dr Toon Van Gorp of the Leuven Cancer Institute, Belgium.  This randomised study evaluated adjuvant pembrolizumab plus chemotherapy for newly diagnosed, high-risk endometrial cancer, showing that while adjuvant pembrolizumab plus chemotherapy did not improve DFS in the intention-to-treat population, it did improve DFS in patients with dMMR tumours, as shown in prespecified subgroup analyses.
For the full article see https://doi.org/10.1016/j.annonc.2024.08.2242

ENGOT-en11/GOG-3053/KEYNOTE-B21: a phase III study of pembrolizumab or placebo + adj CHT +/- RT in patients with newly diagnosed, high-risk endometrial cancer

Professor Florian Lordick discusses his recent editorial in Annals of Oncology that considered the results of theARTIST 2 and CRITICS trials in gastric cancer, both published in the March issue of the journal.
Adjuvant radiotherapy for gastric cancer—end of the road? F. Lordick, M. Nilsson & T. Leong https://doi.org/10.1016/j.annonc.2020.12.006
ORIGINAL ARTICLEAdjuvant chemotherapy is superior to chemoradiation after D2 surgery forgastric cancer in the per-protocol analysis of the randomized CRITICS trial. W. O. de Steur, R. M. van Amelsfoort, H. H. Hartgrink et al. https://doi.org/10.1016/j.annonc.2020.11.004
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. S. H. Park, D.H.Lim, T. S. Sohn et al. https://doi.org/10.1016/j.annonc.2020.11.017

Adjuvant radiotherapy for gastric cancer?

ESMO podcasts offer educational and scientific insights for oncology professionals, covering the latest research, clinical trials, and discussions in cancer care. Topics include highlights from Annals of Oncology and ESMO Open, case-based discussions, expert debates, and content by and for Young Oncologists. Available on Spotify and SoundCloud, these podcasts support continuous learning and multi-professional collaboration in oncology.

ENGOT-en11/GOG-3053/KEYNOTE-B21: a phase III study of pembrolizumab or placebo + adj CHT +/- RT in patients with newly diagnosed, high-risk endometrial cancer

ESMO Podcasts

Related tracks